IL1B and atherosclerosis: A large clinical trial, Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) has proved the effectiveness of anti-inflammatory therapy in treating atherosclerosis (11) and demonstrated the important role of interleukin-1β (IL-1β) in promoting atherosclerosis.